Omnicare Faces Probe Over Possible FCA Offenses, Kickbacks

Law360, New York (April 24, 2013, 5:05 PM EDT) -- Omnicare Inc. on Wednesday said the U.S. Department of Justice is investigating whether the pharmaceutical giant has violated the False Claims Act or federal anti-kickback law in connection with the company’s consumer collections practices.

In a filing with the U.S. Securities and Exchange Commission, Omnicare also disclosed that the DOJ is investigating possible FCA and anti-kickback violations with respect to agreements the company had with Abbott Laboratories, the manufacturer of the anti-seizure drug Depakote.

Omnicare said it is cooperating with both investigations and “believes that it...
To view the full article, register now.